10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2017 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2017 10-K (Filed: Feb 27, 2018) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
| Operating Activities: | |||
| Net income | $ 4,644 | 13,488 | 18,106 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation expense | 233 | 177 | 161 |
| Amortization expense | 1,053 | 981 | 937 |
| Stock-based compensation expense | 638 | 380 | 382 |
| Deferred income taxes | (82) | (119) | (393) |
| In-process research and development impairment | 0 | 432 | 0 |
| Other | 304 | 162 | 562 |
| Changes in operating assets and liabilities: | |||
| Accounts receivable, net | 754 | 1,192 | (1,397) |
| Inventories | (253) | (488) | (855) |
| Prepaid expenses and other | 358 | (520) | (90) |
| Accounts payable | (430) | 47 | 226 |
| Income taxes payable | 5,497 | 1,010 | 269 |
| Accrued liabilities | (818) | 305 | 3,342 |
| Net cash provided by operating activities | 11,898 | 17,047 | 21,250 |
| Investing Activities: | |||
| Purchases of marketable securities | (23,314) | (25,619) | (17,239) |
| Proceeds from sales of marketable securities | 10,440 | 13,039 | 4,792 |
| Proceeds from maturities of marketable securities | 7,821 | 1,700 | 719 |
| Other investments | 0 | (357) | 0 |
| Acquisitions, net of cash acquired | (10,426) | 0 | 0 |
| Capital expenditures | (590) | (748) | (747) |
| Net cash used in investing activities | (16,069) | (11,985) | (12,475) |
| Financing Activities: | |||
| Proceeds from debt financing, net of issuance costs | 8,985 | 5,293 | 9,902 |
| Proceeds from convertible note hedges | 0 | 956 | 784 |
| Proceeds from issuances of common stock | 234 | 208 | 319 |
| Repurchases of common stock | (954) | (11,001) | (10,002) |
| Repayments of debt and other obligations | (1,811) | (1,981) | (997) |
| Payments to settle warrants | 0 | (469) | (3,865) |
| Payment of dividends | (2,731) | (2,455) | (1,874) |
| Other | (330) | (276) | (151) |
| Net cash provided by (used in) financing activities | 3,393 | (9,725) | (5,884) |
| Effect of exchange rate changes on cash and cash equivalents | 137 | 41 | (67) |
| Net change in cash and cash equivalents | (641) | (4,622) | 2,824 |
| Cash and cash equivalents at beginning of period | 8,229 | 12,851 | |
| Cash and cash equivalents at end of period | 7,588 | 8,229 | 12,851 |
| Supplemental disclosure of cash flow information: | |||
| Interest paid, net of amounts capitalized | 1,038 | 885 | 529 |
| Income taxes paid | 3,342 | 2,436 | 3,137 |
| External Links | |
| GILEAD SCIENCES, INC. (GILD) Fiscal Year 2017 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |